Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor–related peptides

Background & Aims: Posttranslational farnesylation is required for Ras activation. Farnesyl transferase inhibitors (FTIs) selectively block protein farnesylation and reduce the growth of many Ras-transformed cells in vitro and in vivo. Activated Ras transforms rat intestinal epithelial (RIE-1) cells by a mechanism distinct from NIH 3T3 fibroblasts in that an epidermal growth factor receptor (EGFR) autocrine loop contributes significantly to the Ras-transformed RIE-1 phenotype. Methods: The ability of FTIs to block growth of Ras-transformed RIE-1 cells was evaluated, and these results were correlated with decreased EGFR ligand production. Results: FTI L744,832 caused a selective, dose-dependent, reversible blockade in proliferation of H-Ras–transformed RIE-1 cells, whereas control cell lines, K-Ras–transformed cells, and activated raf-transfected RIE cells were unaffected. The growth-inhibitory effects of L744,832 correlated with loss of farnesylated H-Ras protein and a marked reduction in transforming growth factor (TGF)-α and amphiregulin expression. Inhibition of proliferation of H-Ras RIE-1 cells by L744,832 was overcome by exogenous TGF-α, and enhanced growth inhibition was achieved by EGFR blockade in combination with L744,832. Conclusions: These data suggest that one mechanism by which FTIs inhibit growth of H-Ras–transformed epithelial cells is by reducing Ras-induced EGFR ligand production. GASTROENTEROLOGY 1999;117:567-576